From April 1998 to March 2000, a cytomegalovirus (CMV) antigenemia-guided pre-emptive approach for CMV disease was evaluated in 77 adult patients who received allogeneic hematopoietic stem cell transplantation at the National Cancer Center Hospital. A CMV antigenemia assay was performed at least once a week after engraftment. High-level antigenemia was defined as a positive result with 10 or more positive cells per 50 000 cells and low-level antigenemia was defined as less than 10 positive cells. Among the 74 patients with initial engraftment, 51 developed positive antigenemia. Transplantation from alternative donors and the development of grade II-IV GVHD were independent risk factors for positive antigenemia. Ganciclovir was administered as pre-emptive therapy in 39 patients in a risk-adapted manner. None of the nine low-risk patients with low-level antigenemia as their initial positive result developed high-level antigenemia even though ganciclovir was withheld. Only one patient developed early CMV disease (hepatitis) during the study period. CMV antigenemia resolved in all but two cases, in whom ganciclovir was replaced with foscarnet. In eight patients, however, the neutrophil count decreased to 0.5 × 10 9 /l or less after starting ganciclovir, including three with documented infections and two with subsequent secondary graft failure. The total amount of ganciclovir and possibly the duration of high-dose ganciclovir might affect the incidence of neutropenia. We concluded that antigenemia-guided pre-emptive therapy with a decreased dose of ganciclovir and response-oriented dose adjustment might be appropriate to decrease the toxicity of ganciclovir without increasing the risk of CMV disease. Bone Marrow Transplantation (2001) 27, 437-444.
Cytomegalovirus (CMV) disease, especially CMV pneumonia, is a major problem after allogeneic hematopoietic stem cell transplantation. 1 Since CMV disease is difficult to treat, prophylactic approaches have been investigated. Ganciclovir has been established as an effective agent for CMV and is the mainstay of CMV prophylaxis. 1 However, the administration of ganciclovir to all bone marrow transplant recipients (prophylactic approach) does not improve survival because of its adverse effects, including myelosuppression and nephrotoxicity. 2, 3 It also raises a problem of late CMV disease. 2, 3 Thus, it is important to discriminate high-risk patients from others to avoid over-treatment. Approaches that involve monitoring of CMV infection and using ganciclovir only in high-risk patients are called preemptive therapies, and are being investigated. 1 A shell vial assay using blood or bronchoalveolar lavage fluid, polymerase chain reaction of leukocytes or sera, and an antigenemia assay have been used to detect high-risk patients. [4] [5] [6] Among these, the CMV antigenemia assay is a rapid and quantitative non-invasive method, [7] [8] [9] which is now used in many institutions as a guide for starting pre-emptive therapy with ganciclovir. 6, [10] [11] [12] [13] [14] [15] [16] However, the dose and timing of ganciclovir administration vary among protocols, and an optimal pre-emptive approach has not yet been determined. We considered that a pre-emptive protocol for Japanese patients should be established based on data from Japanese patients, since the incidence of GVHD, a major risk factor for CMV diseases, is lower in Japanese recipients 17, 18 and the prevalence of positive CMV antibody is high among Japanese. In this study, we analyzed the results of antigenemia-guided pre-emptive therapy in a single center to establish a theoretical background for a pre-emptive protocol. In addition, we describe the serial changes in antigenemia values, which have not been reported in detail.
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Patients and methods
Patients
During a 2 year period (from April 1998 to March 2000), 77 adult Japanese patients underwent allogeneic hematopoietic stem cell transplantation at the National Cancer Center Hospital. Five patients who were receiving their second transplant for relapse after autologous or allogeneic transplant were included. Patient characteristics are shown in Table 1 . All of them were positive for CMV antibody before transplant. Acute leukemia in first remission, chronic myeloid leukemia in the first chronic phase, myelodysplastic syndrome with refractory anemia or refractory anemia with ringed sideroblasts, and severe aplastic anemia were defined as standard-risk diseases. Donors other than HLAidentical siblings were defined as alternative donors.
Hematopoietic stem cell transplantation
The preparative regimens were classified into three groups: total body irradiation (TBI) regimen (n = 50, mainly 120 mg/kg of cyclophosphamide and 12 Gy of TBI), non-TBI regimen (n = 21, mainly 16 mg/kg of busulfan and 120 mg/kg of cyclophosphamide), and reduced intensity regimen (n = 6, 0.66 mg/kg of cladribine, 8 mg/kg of busulfan, and 5 or 10 mg/kg of anti-thymocyte globulin (ATG)). Another four patients received ATG in addition to the TBI regimen as prophylaxis against graft rejection and GVHD with HLA-mismatched transplants. Cyclosporin A was administered as a continuous infusion at a dose of 3 mg/kg/day combined with short-term methotrexate (10-15 mg/m 2 on day 1 and 7-10 mg/m 2 on days 3 and 6, and optionally on day 11) to prevent GVHD. Methylprednisolone (1-2 mg/kg) was added for patients who developed grade II-IV GVHD. Prophylaxis against bacterial, fungal and Pneumocystis carinii infection consisted of fluconazole, ciprofloxacin, and sulfamethoxazole/trimethoprim. As prophylaxis against herpes simplex virus infection, acyclovir was given 750 mg/day intravenously or 1000 mg/day orally from days −7 to 35, followed by long-term low-dose (400 mg/day) oral administration until the end of immunosuppressive therapy. All patients received CMV high-titer intravenous immunoglobulin 5 g weekly for the first 3 months after transplant.
CMV antigenemia assay
An antigenemia assay was performed at least once a week after engraftment by the modified method described previously. 8 Briefly, 1.5 × 10 5 peripheral blood leukocytes were attached to slides using a cytocentrifuge and fixed with cold acetone. From one third to one half of the centrifuged cells were fixed on the slides. The cells were incubated with monoclonal antibody HRP-C7 (Teijin, Tokyo, Japan) raised against immediate-early antigen, and stained by the direct immunoperoxidase method. These cells were analyzed under a light microscope and results are presented as the number of positive cells per 50 000 cells. High-level antigenemia was defined as a positive result with 10 or more positive cells per 50 000 cells and low-level antigenemia as presence of less than 10 positive cells.
Pre-emptive therapy for CMV diseases
High-risk patients were defined as those who were transplanted from alternative donors, those receiving ATG in the preparative regimen, those with grade II-IV acute GVHD, and those receiving more than 0.5 mg/kg of methylprednisolone. The remaining patients were considered low-risk patients. Ganciclovir was started when high-level CMV antigenemia developed in low-risk patients or when five or more positive cells per 50 000 cells were detected in highrisk patients. Administration of ganciclovir in high-risk patients with less than five positive cells was optional. The initial dose of ganciclovir was 5 mg/kg twice daily (high dose). This was continued for at least 1 week until the antigenemia began to decrease and then followed by 5 mg/kg daily (low dose) while antigenemia persisted. In some patients, ganciclovir was administered 2 or 3 days per week while patients were on methylprednisolone therapy for acute GVHD. Granulocyte colony-stimulating factor (G-CSF) was used when the neutrophil count decreased to less than 1 × 10 9 /l.
Diagnosis of CMV disease
Patients with symptoms compatible with CMV disease such as interstitial pneumonitis, gastroenteritis, hepatitis, and retinitis received extensive pathological and microbiological examination of biopsy specimens, to establish a definite diagnosis of CMV disease. However, biopsy of the liver was not performed in patients with thrombocytopenia or ascites. Late CMV disease was defined as that occurring after day 100.
Statistical analysis
Probabilities in the two groups were compared using Fisher's exact test. A backward stepwise logistic regression test was used to determine factors that independently affected the probability of positive antigenemia. Time to the first positive antigenemia was calculated by the Kaplan-Meier method and differences between groups were compared using the log-rank test. Levels of antigenemia in the two groups were compared by the Mann-Whitney U test and the Wilcoxon signed rank sum test for unpaired and paired comparisons, respectively, since the antigenemia values were not expected to fit a Gaussian distribution.
Results
Engraftment, acute GVHD and survival after transplant
Two patients died of regimen-related toxicities before engraftment and one developed primary graft rejection followed by autologous hematopoietic recovery. The remaining 74 patients had successful initial engraftment and were included in the following analyses on CMV antigenemia. Among them, two (2.7%) had secondary graft failure, as described later. Twenty-seven (37%) developed grade II-IV acute GVHD and received methylprednisolone. Another four patients received methylprednisolone for various reasons. The statistical probability of survival of all the 77 patients was 86% at 100 days and 73% at 365 days after transplantation.
Probability of positive antigenemia
Fifty-one patients (69%) developed positive antigenemia at a median onset of 34 days (range 17-74) after transplant. Factors that may have affected the probability of positive antigenemia were examined with Fisher's exact test (Table 2) . Transplant from alternative donors, grade II-IV GVHD, and use of steroids were significantly associated with a high incidence of positive antigenemia. Among these, transplant from alternative donors and grade II-IV GVHD were independent risk factors for positive antigenemia. Use of ATG and HLA disparity were not identified as statistically significant risk factors although more than 10% difference in the incidence of positive antigenemia was observed possibly due to the small number of patients with such risk factors. All of the 17 patients who were transplanted from alternative donors and subsequently developed grade II-IV GVHD were positive for antigenemia. Time from transplant to the first positive antigenemia was evaluated by the Kaplan-Meier method and is shown in Figure 1 . There were statistically significant differences between the two groups. However, when we compared only the patients with positive antigenemia, time from transplant to the first positive antigenemia was not affected by type Bone Marrow Transplantation Table 2 Factors evaluated for their influence on the probability of positive antigenemia of donor or development of grade II-IV GVHD (data not shown).
Initial and maximum values in the antigenemia test in the different groups were compared in recipients who developed positive antigenemia. As shown in Table 3 and Figure 2 , the maximum antigenemia value was significantly higher in recipients who had received bone marrow, those with grade II-IV acute GVHD, and those receiving steroids. When we compared the maximum antigenemia value in all recipients, transplant from alternative donors also correlated with a high maximum antigenemia value (P = 0.0045). None of these factors significantly affected the initial antigenemia value.
Pre-emptive therapy with ganciclovir
Ganciclovir was administered as pre-emptive therapy in 39 patients. At the initiation of ganciclovir treatment, four lowrisk and 11 high-risk patients had high-level antigenemia, whereas 24 high-risk patients had low-level antigenemia. Ganciclovir was administered for a median of 21 days (range 7-91 days) and the median total dose was 175 mg/kg (range 70-465 mg/kg). The median duration of initial highdose ganciclovir was 14 days (range 7-40 days). 
Serial antigenemia values
None of the nine low-risk patients with low-level antigenemia as their initial positive result developed high-level antigenemia even though ganciclovir was withheld (Table 4) . In contrast, 10 of the 22 high-risk patients who presented with low-level antigenemia and did not receive ganciclovir at their first positive antigenemia eventually developed high-level antigenemia, including one with CMV hepatitis, as described below. The difference in the incidence of highlevel antigenemia between low-risk and high-risk patients was statistically significant (P = 0.030). In addition, four of the high-risk patients showed more than 100 positive cells per 50 000 cells. In 14 high-risk patients who began ganciclovir at their first low-level antigenemia, the maximum antigenemia value was 35 positive cells per 50 000 cells. The strategy of beginning ganciclovir at a different antigenemia threshold for high-risk and low-risk patients seemed appropriate.
Serial changes in antigenemia values after starting ganciclovir are shown in Figure 3 relative to the value at the initiation of ganciclovir. Ganciclovir therapy failed to decrease antigenemia value in 15 of 39 patients (39%) within a week. However, seven of them showed subsequent improvement over the next week. The antigenemia value at 1 week after starting ganciclovir did not differ from that Table 3 Relationship between various factors and the initial positive and maximum antigenemia values. at the initiation of ganciclovir treatment (P = 0.21). Thus, we considered that at least 2 weeks are needed to observe a response to ganciclovir. In two patients, ganciclovir was replaced with foscarnet because of a rapid increase in antigenemia despite ganciclovir treatment for 7 and 14 days, respectively, and antigenemia values were suppressed by foscarnet. In the remaining 37 patients, ganciclovir resolved the antigenemia. However, positive antigenemia recurred after discontinuation of ganciclovir in 16 patients. Three of them developed recurrent high-level antigenemia, including one with late CMV retinitis. All of these three patients were receiving methylprednisolone for treatment of acute GVHD when they experienced recurrent positive antigenemia. We considered that maintenance ganciclovir should be continued in patients with persisting high-risk features.
Factors
CMV diseases
One patient, who was transplanted from an unrelated donor with one mismatched HLA antigen, developed CMV hepatitis on day 50 (proven by liver biopsy) while receiving methylprednisolone to treat acute GVHD. At diagnosis, antigenemia value was 23 positive cells per 50 000 cells. Ganciclovir treatment improved liver enzymes and the antigenemia resolved. Another patient developed CMV retinitis on day 329, and subsequently died of complicated bacterial pneumonia. The remaining patients did not experience either early or late CMV disease. Therefore, the sensitivity and specificity of the CMV antigenemia assay in predicting CMV disease was 100% and 32%, respectively. No fatal CMV disease was observed during the study period.
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Neutropenia after pre-emptive therapy with ganciclovir
In eight patients (21%), the neutrophil count decreased to 0.5 × 10 9 /l or less at a median interval of 21 days (range 14-60 days) after starting ganciclovir. Documented infections during the neutropenic period occurred in three (7.7%), one of which was fatal pneumonia. Two had secondary graft failure following ganciclovir-induced neutropenia, although the relationship was not definite. The total dose of ganciclovir was significantly higher in patients who developed neutropenia than in those without neutropenia (P = 0.02, Figure 4 ). Concerning the duration of ganciclovir administration at the initial high dose, seven of the 27 patients (26%) who received the initial dose for more than a week developed neutropenia, whereas only one of the 12 (8%) who received the initial dose for a week experienced neutropenia. The difference was not statistically significant (P = 0.39), probably because of the small patient number. Although it has been suggested that timing of ganciclovir administration may affect incidence of neutropenia, 19 the timing of starting ganciclovir did not differ between the two groups. Therefore, we considered that a shorter use of high-dose ganciclovir might decrease the incidence of neutropenia.
Discussion
We have presented the results of an antigenemia-guided pre-emptive therapy in Japanese patients. CMV disease was observed in only two patients, one with early, and the other with late disease. Both were successfully treated with ganciclovir. Nevertheless, the myelotoxicity of ganciclovir was significant. Approximately 20% of the patients who received ganciclovir developed neutropenia, and one developed fatal pneumonia.
We should note that the antigenemia value has been described differently in previous studies. This was based on the number of positive cells per cells applied to a cytocentrifuge in some reports and the number of positive cells per cells actually counted in others. Only approximately one third of the centrifuged cells were actually attached on to slides in our method. In addition, antigenemia level is influenced by several factors, such as storage and fixation method. 20 It is also affected by the monoclonal antibodies used to detect the CMV antigen. 21, 22 Furthermore, presence of CMV antigenemia has been reported as inappropriate for detecting CMV gastroenteritis or retinitis. 6, 15 Several reports have shown the results of antigenemiaguided pre-emptive therapy. 6, [10] [11] [12] [13] [14] [15] [16] As shown in Table 5 , ganciclovir was started at low-level antigenemia in most pre-emptive protocols except for those in Japan. Threshold antigenemia value in Japanese protocols might be based on the data by Gondo et al, 8 who showed that CMV disease was frequent in patients with 10 or more positive cells per 50 000 cells. They later showed that CMV disease occurred with low-level antigenemia in unrelated transplant settings. 9 Our strategy used two distinct thresholds for starting ganciclovir according to risk of CMV disease. Withholding ganciclovir in low-risk patients with low-level antigenemia seems to have been appropriate, since none of these went on to develop high-level antigenemia. In contrast, approximately half of the untreated high-risk patients developed high-level antigenemia, including one with CMV hepatitis. Therefore, it seems appropriate to start ganciclovir in highrisk patients with low-level antigenemia.
Transplants from unrelated donors, HLA-mismatched transplants, use of T cell-depleted grafts, and acute GVHD have been shown to be risk factors for development of CMV disease. In this study, transplants from other than HLA-identical siblings and development of grade II-IV GVHD were identified as independent risk factors for positive antigenemia. Although we could not identify risk factors for CMV disease because of its low incidence, the two risk factors above were associated with a significantly higher maximum antigenemia value despite early administration of ganciclovir. Therefore, patients with such risk factors should be monitored carefully for symptoms that may be associated with CMV disease.
Serial changes in antigenemia values after starting ganciclovir showed that more than 2 weeks were required to evaluate response to ganciclovir. Goodrich et al 23 showed a similar trend in serial cultures used to detect CMV infection. However, CMV infection was eliminated after 3 weeks of ganciclovir in their study, whereas antigenemia was still detected at that time in our series. The difference might result from the higher sensitivity of the antigenemia assay compared with culture method of detection. 24 Incidence of early CMV diseases was 1.4% in the present study. The reported incidence of CMV disease naturally depends on degree of aggressiveness in identifying for CMV disease. For example, Mori et al 15 reported a high incidence (14%) of CMV gastroenteritis, which may be due to their aggressive approach for detecting upper gastrointestinal disease. 25 We used a relatively aggressive approach to detect CMV disease, although we might have overlooked mild CMV gastroenteritis. In addition, number of mismatched or unrelated transplants influences the incidence of CMV disease. Previous studies in which more than half of the transplants were mismatched or unrelated showed a higher incidence of CMV disease than did this series. The routine use of CMV high-titer intravenous immunoglobulin might have resulted in a favorable outcome. However, two meta-analyses failed to show any beneficial effect of immunoglobulin in preventing CMV disease in CMV-seropositive recipients. 26, 27 The role of immunoglobulin in the prophylaxis of CMV disease has become more questionable after the introduction of pre-emptive therapy based on antigenemia or quantitative PCR. The rationale of our routine use of immunoglobulin was to decrease the incidence of GVHD and, possibly, infections due to pathogens other than CMV. In most protocols that have been published previously, the duration of initial high-dose ganciclovir was fixed. We used a response-oriented approach to continue high-dose ganciclovir until the antigenemia value began to decline. The median duration of high-dose administration was 14 days, which is similar to previous studies. However, some patients required ganciclovir for 3 weeks or longer. Continuation of high-dose ganciclovir in poor-response patients might prevent CMV diseases. On the other hand, neutropenia developed in eight of the 39 patients who received ganciclovir, including three with documented infections. The total amount of ganciclovir and possibly the duration of high-dose ganciclovir might affect the incidence of neutropenia. Therefore, dose of ganciclovir should be as low as possible in low-risk patients. The initial dose of ganciclovir should also be discussed. High-dose ganciclovir has been used in most pre-emptive approaches, but the dose has been as high as that used to treat CMV pneumonia. Verdonck et al 10 administered ganciclovir to 19 recipients with positive antigenemia or who were receiving steroid therapy for acute GVHD at an initial dose of 2.5 mg/kg twice daily. Only one of the 19 patients had positive antigenemia after 14 days, and eventually received a higher dose. Since all of the patients in their study were transplanted from an HLA-identical sibling, pre-emptive therapy with low-dose ganciclovir should be studied further in transplants from alternative donors, although it is possible that the incidence of CMV disease will increase.
Based on these findings, we suggest a novel responseoriented and antigenemia-guided pre-emptive therapy with U-BMT = unrelated bone marrow transplantation; ND = not described.
Bone Marrow Transplantation initial low-dose ganciclovir. The dose of ganciclovir is adjusted weekly according to changes in the antigenemia value, since some patients may require high-dose ganciclovir for a longer duration. We are planning a feasibility study of this novel approach, followed by a randomized study for comparison with the former approach.
